The Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome - Full Text View

The Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome (VCFS)

The recruitment status of this study is unknown because the information has not been verified recently.

Verified October 2008 by Rabin Medical Center. Recruitment status was Recruiting

First Received on October 7, 2008. No Changes Posted

Sponsor:	Rabin Medical Center
Information provided by:	Rabin Medical Center
ClinicalTrials.gov Identifier:	NCT00768820

Purpose

The purpose of this study is to investigate the Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome (VCFS), Williams Syndrome (WS)and Fragile X Syndrome Characterization, Treatment and Examining the Connection to Developmental and Molecular Factors

Condition	Intervention	Phase
Velocardiofacial Syndrome Williams Syndrome Fragile X Syndrome	Drug: methylphenidate, fluoxetin, risperidone	Phase IV

Study Type:	Interventional
Study Design:	Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Diagnostic
Official Title:	The Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome (VCFS), Williams Syndrome (WS)and Fragile X Syndrome Characterization, Treatment and Examining the Connection to Developmental and Molecular Factors

Resource links provided by NLM:

Genetics Home Reference related topics: 17q21.31 microdeletion syndrome 22q11.2 deletion syndrome Baller-Gerold syndrome Crouzon syndrome fragile X syndrome MECP2 duplication syndrome PPM-X syndrome tetrasomy 18p Williams syndrome

MedlinePlus related topics: Fragile X Syndrome

Drug Information available for: Methylphenidate Risperidone Methylphenidate hydrochloride

U.S. FDA Resources

Further study details as provided by Rabin Medical Center:

Primary Outcome Measures:

Measure that are used: psychological measures, molecular tests, responsiveness to medical treatments [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]

Estimated Enrollment:	400
Study Start Date:	May 2001
Estimated Primary Completion Date:	January 2010 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: 1	Drug: methylphenidate, fluoxetin, risperidone first cognitive evaluation without methylphenidate,second cognitive evaluation with methylphenidate

Eligibility

Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

chromosomal deletion proven by FISH examination

Exclusion Criteria:

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00768820

Contacts

Contact: Doron Gothelf, MD

972-03-9253186

gothelf@post.tau.ac.il

Locations

Israel
Schneider Children's Mediac Center of Israel	Recruiting
Petach-Tikva, Israel, 49202
Contact: Doron Gothelf, MD 972-03-9253186

Sponsors and Collaborators

Rabin Medical Center

More Information

No publications provided

Responsible Party:	Doron Gothelf, Rabin Medical Center
ClinicalTrials.gov Identifier:	NCT00768820 History of Changes
Other Study ID Numbers:	SCMCI082455CTIL
Study First Received:	October 7, 2008
Last Updated:	October 7, 2008
Health Authority:	Israel: Israeli Health Ministry Pharmaceutical Administration

Keywords provided by Rabin Medical Center:

Velocardiofacial syndrome
Williams syndrome
fragile X syndrome
cognitive phenotype
psychiatric phenotype

Additional relevant MeSH terms:

Fragile X Syndrome
Williams Syndrome
DiGeorge Syndrome
Mental Retardation, X-Linked
Mental Retardation
Neurobehavioral Manifestations
Neurologic Manifestations
Nervous System Diseases
Sex Chromosome Disorders
Chromosome Disorders
Congenital Abnormalities
Genetic Diseases, Inborn
Genetic Diseases, X-Linked
Heredodegenerative Disorders, Nervous System
Aortic Stenosis, Supravalvular

Aortic Valve Stenosis
Heart Valve Diseases
Heart Diseases
Cardiovascular Diseases
22q11 Deletion Syndrome
Craniofacial Abnormalities
Musculoskeletal Abnormalities
Musculoskeletal Diseases
Heart Defects, Congenital
Cardiovascular Abnormalities
Lymphatic Abnormalities
Lymphatic Diseases
Abnormalities, Multiple
Hypoparathyroidism
Parathyroid Diseases

ClinicalTrials.gov processed this record on February 09, 2012